Earli, a Bay Area biotech developing novel cancer drugs, is seeking to raise a $60 million Series B round, CEO Cyriac Roeding tells Axios Pro exclusively.
Why it matters: Earli is talking to several large pharma companies about potential collaborations, Roeding says.
